Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7396 to 7410 of 7675 results

  1. GaitSmart assessment and vGym personalised exercise rehabilitation programme for people with gait and mobility issues (MIB283)

    This medtech innovation briefing (MIB) has been replaced by NICE medical technologies guidance on GaitSmart rehabilitation exercise programme for gait and mobility issues.

    Medtech innovation briefing
    Published
    1 February 2022

  2. AposHealth for knee osteoarthritis (MIB284)

    This medtech innovation briefing has been updated and replaced by NICE medical technologies guidance 76. 

    Medtech innovation briefing
    Published
    1 February 2022

  3. QbTest for the assessment of attention deficit hyperactivity disorder (ADHD) (MIB318)

    This guidance has been updated and replaced by NICE diagnostics guidance 60.

    Medtech innovation briefing
    Published
    7 March 2023

  4. TriageHF Plus for remotely monitoring people with cardiac implantable electronic devices at risk of heart failure or worsening heart failure (MIB298)

    This medtech innovation briefing has been replaced by NICE diagnostic guidance on heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices.

    Medtech innovation briefing
    Published
    31 May 2022

  5. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)

    This guidance has been updated and replaced by NICE technology appraisal guidance 780.

    Technology appraisal guidance
    Published
    15 May 2019

  6. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    In development [GID-TA11146] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Technology appraisal guidance
    Published
    8 May 2019

  8. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development [GID-TA10568] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632

    In development [GID-TA11631] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development [GID-TA11015] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]

    In development [GID-TA11014] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    In development [GID-TA11093] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Venglustat for treating gangliosidoses in people 2 years and over ID 6358

    In development [GID-TA11601] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    In development [GID-TA11074] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

    In development [GID-TA11009] Expected publication date: TBC

    Technology appraisal guidance
    In development